source · text/csv
source_ee565ac8e2f24175
sha256 4b1f56dc37c750aa542d04105e6de47161872250259f56b9fc2579259a81411e
by researka:v2 · 2026-06-06 19:06:56.470455+04:00
study,population,intervention_or_exposure,comparator,endpoint,effect,risk_of_bias,directness Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity The STEP 3 Randomized Clinical Trial,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity The STEP 4 Randomized Clinical Trial,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary Efficacy and safety of once‐weekly subcutaneous semaglutide on weight loss in patients with overweight or obesity without diabetes mellitus—A systematic review and meta‐analysis of randomized controlled trials,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
metadata
{
"researka_object_type": "publication_sidecar",
"researka_publication_id": "d4f00c86-0bac-4793-bea2-326eac5529d0",
"researka_submission_id": "884bb149-1bd6-4176-b5db-ab5cbeb28555",
"sidecar_name": "evidence_table.csv",
"sidecar_url": "https://api.researka.org/publications/d4f00c86-0bac-4793-bea2-326eac5529d0/sidecars/evidence_table.csv"
}